Evidence map›Paper›PMID 42100730›Full record

ArticleFrontiers in neuroscience2026

Tideglusib improves novel object recognition memory in the preclinical DBA/2J

Emily N Copeland, Amélie A T Marais, Ahmad Mohammad, Bianca M Marcella, Ryan W Baranowski, Shawn M Beaudette, Rebecca E K MacPherson, Val A Fajardo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Emily N CopelandDepartment of Kinesiology, Brock University, St. Catharines, ON, Canada.
Amélie A T MaraisDepartment of Kinesiology, Brock University, St. Catharines, ON, Canada.
Ahmad MohammadDepartment of Health Sciences, Brock University, St. Catharines, ON, Canada.
Bianca M MarcellaDepartment of Kinesiology, Brock University, St. Catharines, ON, Canada.
Ryan W BaranowskiDepartment of Kinesiology, Brock University, St. Catharines, ON, Canada.
Shawn M BeaudetteDepartment of Kinesiology, Brock University, St. Catharines, ON, Canada.
Rebecca E K MacPhersonDepartment of Health Sciences, Brock University, St. Catharines, ON, Canada.
Val A FajardoDepartment of Kinesiology, Brock University, St. Catharines, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Duchenne muscular dystrophy (DMD) is a severe X-linked neuromuscular disorder characterized by progressive muscle wasting. Approximately 1 in 3 DMD patients experience cognitive dysfunction, with research suggesting an Alzheimer's disease (AD)-like pathology. We have previously shown that treatment with the glycogen synthase kinase 3β (GSK3) inhibitor, tideglusib, improves muscle quality, function, and insulin sensitivity in the DBA/2J (D2) Methods: Male D2 WT and Results: Compared to vehicle-treated Discussion: The results from this brief follow-up study offer preliminary support for tideglusib as a treatment for both muscle and brain impairments in

Indexed as

Alzheimer’s diseaseDMDGSK3recognition memorytideglusib

Identifiers

PMID42100730
PMCPMC13144132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.